Plamed Group Logo

73.89% Less CML in Glycated Skin: the Denominator, the Residue, and the Control That Scored Higher

November 11, 2026Ingredient Insights

A silibinin-standardised extract was dosed at 0.05% onto human skin explants under methylglyoxal and UV stress. CML fell by 73.89% against a glycated control sitting at 6.55× baseline, leaving a residue of 1.71×. In the same run, the assay control inhibited 80.31% — more than the ingredient did. This article sets out what those three numbers say together, what they do not, and how to formulate so they still apply in a finished emulsion.

At a glance

INCI

Silymarin

Active

Silibinin, specification ≥80.0% (A + B); 81.11% measured on the reference lot

Product

PMAnti-AGEs® Silibinin80 (PMKZ3101)

Model

Ex vivo human skin explants; methylglyoxal 2 mM plus UVA 30 J/cm² and UVB 50 mJ/cm², four cycles over four days

CML at 0.05%

1.71× baseline, 73.89% below the glycated control (P < 0.01, n = 3)

Assay control

Aminoguanidine sulfate 3 mM: 1.29× baseline, 80.31% below the glycated control

Matrix proteins

11 of 11 increased at 0.05% (P < 0.01); collagen XVII +266.67%, collagen III +235.00%

Dose as silibinin

0.05% of the ingredient ≈ 0.04% silibinin equivalent at ≥80%

Reference use range

0.1–0.5% of the ingredient; the efficacy figures below were generated at 0.05%

Solubility

1.0–1.1 g/100 g in propanediol or butanediol; insoluble in water and in oils

Table 1. The ingredient and the study behind every figure in this article. Single source: Biocell report G4814-2604274.

What glycation does to dermal protein — and why CML is not “AGEs”

Short answer

Glycation is a non-enzymatic reaction in which reducing sugars and reactive dicarbonyls bind to lysine and arginine residues on dermal proteins, forming crosslinks that stiffen the extracellular matrix. Its end products are a family, not a single molecule. CML — Nε-carboxymethyl-lysine — is one member, and the one most often quantified.

Glucose reacts slowly. Dicarbonyls such as methylglyoxal and glyoxal react orders of magnitude faster, which is why almost every controlled glycation experiment uses one of them as the challenge rather than sugar alone. In dermal tissue the consequence is mechanical before it is visible: collagen fibres crosslink, the elastic network loses recoil, and the dermis stiffens from the inside.

The end products of that chemistry are not one substance. CML, pentosidine, pyrraline, argpyrimidine and the hydroimidazolones are all advanced glycation end products, formed by different routes from different precursors, and they behave differently in tissue. CML is the one measured most often, for a practical reason: a validated antibody exists, so it can be stained and quantified in situ. Pentosidine can be read by its fluorescence instead, which is cheaper and less specific.

A product that lowers CML by 73.89% has shown something specific. It has not shown a 73.89% reduction in “AGEs”.

That distinction is not pedantry; it decides whether a claim survives review. “Reduces CML, one of the advanced glycation end products” is a statement about a measured endpoint. “Reduces AGEs” is a statement about a family of compounds, most of which were never assayed. The first is defensible with one report. The second needs a panel.

Glycation is also not oxidation, although the two are sold together. An antioxidant assay — ORAC, DPPH, a FRAP value — measures radical scavenging and says nothing about whether a carbonyl has been prevented from attaching to a lysine. Plamed keeps the two as separate evidence streams, because a formulator who needs an anti-glycation claim cannot substitute an antioxidant number for it.

The model: one concentration, two controls, and a denominator that matters

Short answer

The study used human skin explants rather than cultured cells. Tissue was challenged with 2 mM methylglyoxal together with UVA at 30 J/cm² and UVB at 50 mJ/cm², four cycles over four days. This article reports the 0.05% group, where three replicates per group were read against both a blank and a glycated control.

Plamed commissioned the work on PMAnti-AGEs® Silibinin80 from Shaanxi Biocell General Testing Technology, and report G4814-2604274 is the single source for every figure here. Explants were maintained in six-well plates with 3.7 mL of medium at 37 °C and 5% CO₂, medium changed daily, and equilibrated for two days before treatment began.

Group

Treatment

What it is for

Blank (BC)

Medium only, no challenge

Untreated baseline for CML and for the matrix proteins

Negative control (NC)

Methylglyoxal 2 mM + UVA + UVB

The glycation challenge, and the denominator for every inhibition figure

PC1

Vitamin C 100 µg/mL + vitamin E 7 µg/mL + challenge

Positive control for the eleven matrix proteins

PC2

Aminoguanidine sulfate 3 mM + challenge

Positive control for CML

Sample 0.05%

Topical, plus challenge

The group reported in this article

Table 2. Test groups. Two positive controls, one per endpoint family, are the reason the results can be interpreted at all. The study ran a second, higher concentration; its results are not reported here.

Each cycle ran the same way: sample applied to the surface, methylglyoxal added to the medium, tissue incubated 24 hours, then irradiated. Four cycles over four days, after which residual material was washed off, the tissue fixed in 4% paraformaldehyde for 24 hours, and sections stained. CML and the collagens were read by immunofluorescence at 200×; hyaluronic acid binding protein by biotin chromogenic staining. Intensity was expressed as integrated optical density per area and compared with a two-tailed t-test in GraphPad Prism.

Dose needs translating before it can be compared with anything. 0.05% is a concentration of the ingredient, not of silibinin: at ≥80% silibinin it corresponds to roughly 0.04% silibinin equivalents. Shin and colleagues, in the study that characterised silibinin against methylglyoxal-induced glycation in explants, used 1% of a milk thistle flower extract containing 0.1% silibinin. The concentration tested here therefore sits below that published explant dose, not above it. Plamed publishes the conversion because a dose quoted without it cannot be compared with anything else.

What “n = 3” and a two-tailed t-test actually buy you

Three replicates per group is the minimum for this design, and it is what the published protocol used as well, so the two studies are comparable in structure. What it buys is a statement of the form “the difference from the glycated control is larger than the within-group variation in this tissue”. What it does not buy is a population inference, a rank order against an active tested in another laboratory, or a prediction about a different donor.

Explant response varies between donors, and a single study is a signal rather than a distribution. This is why Plamed reports the whole design — challenge, controls, replicates, statistics — next to the number, and why the number alone should not travel without them.

The result: 73.89% off a six-fold challenge, and a residue of 1.71×

Short answer

In the glycated control, CML rose to 6.55× the untreated baseline. At 0.05% the ingredient lowered it by 73.89% against that control (P < 0.01), leaving CML at 1.71× baseline. The control inhibited 80.31%, landing at 1.29× baseline.

Group

Relative IOD / area
(mean ± SD)

Inhibition
vs NC

P vs NC

Blank (BC)

1.00 ± 0.08

—

—

Negative control

6.55 ± 0.31

—

0.000 vs BC

PC2 · aminoguanidine 3 mM

1.29 ± 0.18

80.31%

< 0.01

Sample 0.05%

1.71 ± 0.15

73.89%

< 0.01

Table 3. CML by immunofluorescence, integrated optical density per area. Inhibition is calculated against the negative control, not against blank. Source: Biocell report G4814-2604274, table 26.

PMAnti-AGEs® Silibinin80 · glycated human skin explants, 4 days

At 0.05%, CML sits at 1.71× baseline — the glycated control it is measured against sits at 6.55×

CML by immunofluorescence, integrated optical density per area, as fold of the untreated control (dashed line = 1.0). Inhibition percentages are versus the glycated control, which is the denominator, not versus untreated tissue. The assay control inhibited more than the ingredient did. P < 0.01, n = 3.

0 1 2 3 4 5 6 7 6.55 -73.89% 1.71 -80.31% 1.29 Untreated blank control Glycated MGO + UV, no active 0.05% Silibinin80 Aminoguanidine 3 mM, assay control

Source: Shaanxi Biocell General Testing Technology, report G4814-2604274, table 26. Values are means; inhibition calculated against the glycated control. The study ran more than one concentration; this chart reports the 0.05% group. Figure prepared by Plamed.

Figure 1. CML in glycated human skin explants. The dashed line marks the untreated control at 1.0, so a bar below it would mean less CML than unchallenged tissue. At 0.05% the residue sits at 1.71× that line; the assay control sits at 1.29×. Source: Biocell report G4814-2604274, table 26.

Read the first two rows before the last two. The challenge multiplied CML by 6.55, which is what makes an inhibition percentage meaningful; without that rise, the same percentage would be arithmetic on noise. Then read the sample row against the control row rather than against the chart's impression: 73.89% is a reduction from a six-fold elevated baseline, and it does not return the tissue to 1.00.

Why 1.71× baseline says more than 73.89%

A percentage moves with its denominator. 73.89% of a six-fold elevation still leaves a residue, and the useful question for a formulator is where that residue sits relative to untreated tissue. Here it sits at 1.71× — against 6.55× with no treatment. That is the sentence Plamed puts in front of an R&D reviewer, because it describes a position rather than a ratio.

It is not zero, and the design does not allow “removal”. The tissue was dosed while glycation was being induced, not after it had accumulated. Four days of simultaneous protection is a different claim from clearing what is already crosslinked, and only the first one is on the table.

The control that scored higher — and why it stays in the report

Short answer

Aminoguanidine sulfate at 3 mM, run as the positive control, inhibited CML by 80.31%. That is 6.42 points more than the ingredient achieved at 0.05%. Plamed reports it because a percentage is only informative if the assay could have detected an effect of that size — and because a number is more useful when its reference point is visible.

Assay validity has two halves, and reports often show only one. The challenge has to work: the negative control must differ from blank, and here it does, at P = 0.000. The method has to be able to see an effect of the size being claimed: a known inhibitor, run in the same batch on the same tissue, must move the endpoint. Without the second half, a null result and an insensitive assay look identical.

Aminoguanidine is a reference glycation inhibitor from the pharmacology literature. It is not a cosmetic ingredient and Plamed does not position it as one. It appears in the design for one reason: a method that cannot detect a known inhibitor cannot be trusted to detect a new one. The 80.31% is evidence about the assay, not about the market.

A 73.89% that arrives without the 80.31% is not a stronger result. It is a less readable one.

The gap is also not a defeat, and it is worth being precise about why. The two figures were produced in the same assay on the same tissue but at different molar concentrations of two different molecules, and the design contains no head-to-head dose series for both. A superiority claim would need that series; this study is not that design. What the 80.31% establishes is narrower and more useful: the endpoint can move, by about this much, under this challenge.

Plamed keeps the control in the table for the same reason it keeps the residue: both are what a reviewer will ask for, and a supplier who omits them has left the reader to assume the best case.

The same samples: eleven matrix proteins up at 0.05%

Short answer

All eleven extracellular matrix proteins measured increased at 0.05% (P < 0.01): collagen XVII by 266.67%, collagen III by 235.00%, hyaluronic acid binding protein by 221.74%, fibrillin-1 by 200.00%, against the glycated control.

Marker

0.05% vs NC

Compartment

Collagen XVII

+266.67%

Hemidesmosome / basement membrane

Collagen III

+235.00%

Interstitial dermis

HABP

+221.74%

Hyaluronic acid binding protein

Fibrillin-1

+200.00%

Microfibrils at the DEJ

Collagen VI

+200.00%

Microfibrillar network

Collagen I

+168.18%

Interstitial dermis

Elastin

+154.55%

Elastic fibre

Collagen IV

+131.58%

Basement membrane

Collagen XV

+130.00%

Multiplexin, basement membrane zone

Collagen V

+63.89%

Interstitial dermis

Collagen VII

+47.37%

Anchoring fibrils

Table 4. Eleven matrix proteins at 0.05%, immunofluorescence except HABP (biotin chromogenic). All comparisons P < 0.01 versus the negative control. Source: Biocell report G4814-2604274.

Two features of this panel matter more than the ranking. The first is coverage: basement membrane (IV, XVII), interstitial collagens (I, III, V), anchoring fibrils (VII), the microfibrillar collagens (VI, XV), elastin, fibrillin-1 and hyaluronic acid binding protein were all read in the same sections. A single-marker panel can be moved by a single artefact; eleven moving together is harder to explain away. Plamed reports all eleven rather than the three that moved most, because a panel that shows only its best markers is not a panel.

The second is the pairing with CML. Fibrillin-1 is unusually sensitive to glycation — Shin and colleagues showed that methylglyoxal reduces fibrillin-1 at the dermal–epidermal junction while CML rises, and that the two run in opposite directions. This study reproduced that opposition at a single concentration: CML down 73.89%, fibrillin-1 up 200.00%, both at 0.05%, both in the same tissue. That is a mechanistic consistency check rather than a marketing point, and it is the strongest single reason to trust the panel.

What the panel is not: immunofluorescence measures protein present in the section, not the rate at which new protein is being made, and not the mechanical property of the tissue. A 266.67% increase in collagen XVII staining is not a 266.67% increase in firmness, and it should never be written as one.

What the data does not prove

Short answer

It does not show that the ingredient removes glycation that already exists, that it lowers AGEs other than CML, that a finished emulsion behaves the way the test system did, or how performance changes with concentration above 0.05%. Dosing began with induction, ran four days, and stayed ex vivo.

Plamed limits its claim for this ingredient to the five boundaries below.

Not removal. Protection was concurrent with the challenge. A study that glycates first and applies the ingredient afterwards answers a different question, and this one does not attempt it.

Not every AGE. One marker was measured. Pentosidine, argpyrimidine, the hydroimidazolones and total AGE fluorescence were not. Any sentence that generalises from CML to the family is unsupported by this report.

Not a finished formula. The test article was the raw material applied to the surface. Whether 0.05% of it survives emulsification, reaches the viable epidermis, and holds its concentration over a shelf life is a formulation question, addressed in the next section but not answered by this study.

Not human. Explanted tissue is closer to skin than a monolayer and further from a person than a patch test. At the time of writing there is no in-vivo data set for this ingredient, and Plamed does not imply one.

Not a dose response. The concentration reported here is 0.05%, and the reference use range runs to 0.5%. The figures above describe what happened at 0.05%; they are not a prediction of what happens at the top of the range, and Plamed does not present them as one.

Formulating so the data still applies

Short answer

Dose at the level the brief calls for, pre-disperse the powder in propanediol or butanediol at 1:20 or leaner, and add it after emulsification. It will precipitate in any aqueous base regardless of pH, and colour is stable only up to pH 8.

Solvent

Solubility (g/100 g)

Practical note

Water

Insoluble

Do not build an aqueous system around it

1,3-Propanediol

1.0 – 1.1

Preferred; sonicate over 8 h or warm to dissolve

1,3-Butanediol

1.0 – 1.1

Preferred; interchangeable with propanediol in practice

1,2-Pentanediol

0.3 – 0.4

Partial; not a primary solvent

1,2-Hexanediol

0.1 – 0.2

Slow and limited; not recommended as primary

GTCC (caprylic/capric triglyceride)

< 0.01

Not for oil-only systems

Table 5. Solubility in cosmetic solvents at room temperature with sonication. Data from Plamed’s internal solubility screen.

The number that changes practice for PMAnti-AGEs® Silibinin80 is not the 1.0 g/100 g figure but the dispersion ratio. In Plamed’s application work, a 1:20 product-to-glycol ratio dispersed evenly with no short-term precipitate, while 1:10 precipitated within minutes; 1,2-pentanediol precipitated even at 1:40. So Plamed’s handling instruction is a ratio, not a percentage: pre-disperse at 1:20 or leaner, do not aim for a clear solution, and add the slurry after the emulsion has formed.

  1. Disperse the powder in propanediol or butanediol at 1:20 (product : glycol). Warm to 40–45 °C and stir for about 30 minutes if a smoother slurry is needed; complete dissolution is not required.

  2. Complete the emulsification first. Add the dispersion at the cool-down stage with stirring, then homogenise briefly to distribute the particles.

  3. Check the final pH. Keep it at or below 8, and keep alkaline raw materials out of direct contact with the pre-dispersion.

Where it will fail: water, oil, and pH 9

Clear aqueous systems. A gel, a toner or a transparent serum will show precipitate regardless of pH, because the event is a solubility limit and not a pH reaction. This is the single most common formulation error with silymarin, and it is not fixable with a chelator or a solubiliser swap at the same use level.

Pure oil systems. Silicone, synthetic esters, vegetable oils and GTCC all gave cloudy dispersions in Plamed’s tests, and no photographs were retained because the result was uniformly negative. An anhydrous balm is not a candidate.

pH 9 and above. Colour is stable from pH 3 to 8 and darkens visibly above that, so the ingredient should not be put in direct contact with alkaline raw materials. For emulsions that drift upward over shelf life, buffer rather than rely on the initial reading.

For process temperature, Plamed’s guidance is to add at cool-down; finished-formula stability data above 45 °C is not yet available, and the ingredient should not be described as heat-stable on the strength of a raw-material assay. Antioxidant co-use — vitamin E or a sulfite — is the usual way to slow colour development in a system that also contains easily oxidised oils.

How to word the claim in your own file

Short answer

Put the concentration, the model, the duration, the control and the report number in one sentence. Under Regulation (EU) No 655/2013 a claim has to be supported by evidence that matches its wording, so the narrowest sentence is also the most defensible one.

Tempting wording

What the data supports

Why

“Reduces AGEs”

“Reduced CML, one of the advanced glycation end products, by 73.89% at 0.05% in glycated human skin explants”

CML is one marker, not the family

“Proven anti-glycation effect”

“Reduced CML by 73.89% against a glycated control in ex vivo human skin over four days”

Ex vivo is not clinical; no human study exists

“Boosts collagen 2.6×”

“Increased collagen XVII by 266.67% versus the glycated control at 0.05%”

Denominator is the challenged control, and the readout is staining intensity

“Removes existing glycation”

“Inhibited CML formation during a four-day glycation challenge”

Dosing was concurrent with induction

“Beats the reference inhibitor”

“Reached 73.89% against an assay control of 80.31% in the same run”

Different molecules, different concentrations, no head-to-head series

“Reduces wrinkles”

Not supported by this data set

No wrinkle endpoint was measured

Table 6. Substitutions that keep the claim inside the evidence. The left column quotes wording that Plamed does not use, shown so that the replacement is explicit.

Plamed keeps the sentence and its evidence together, and supplies the report itself rather than a summary of it: request the full report from Plamed. In a product information file, the claim, the report number, the concentration and the model should sit in one block; if the sentence changes, the summary changes with it. The version of this that survives review is narrower than the version that reads best, and that is the normal trade.

The figures here come from a single production lot submitted as a representative sample. They are not an industry benchmark and not a specification minimum; treat them as this lot, this design, this laboratory.

Frequently asked

Is CML the same as AGEs?

No. CML — Nε-carboxymethyl-lysine — is one advanced glycation end product among several, and the one most often measured because a validated antibody makes it quantifiable in tissue. A CML result is a statement about CML.

Can I claim “reduces AGEs” on pack?

Not as written. “Reduces CML, one of the advanced glycation end products” is supportable by report G4814-2604274 at 0.05%. The unqualified version asserts an effect on compounds that were never assayed.

Why does this article report only one concentration?

The study ran a second, higher concentration in the same design. This article reports the 0.05% group, and every figure in it — including the claim wording in Table 6 — is scoped to that concentration. A supplier who reports one concentration should say so, which is what this paragraph does.

What use level should I start with?

The reference use range for the ingredient is 0.1–0.5%. The efficacy figures reported here were generated at 0.05%, so a formula dosed in the reference range sits above what this study measured; Plamed does not present the 0.05% results as a performance prediction for a higher dose.

Is Silymarin water soluble?

No. Solubility is 1.0–1.1 g/100 g in propanediol or butanediol and effectively zero in water. It is used as a dispersion in a glycol, added to an emulsified base.

Can it go into a clear serum or a gel?

Not at a use level that carries the data. Any aqueous system will show precipitate, and pH adjustment does not prevent it. Emulsion systems with a thickener are the workable route.

Is aminoguanidine a competing ingredient?

No. It is a reference inhibitor used to prove the assay can detect an effect, and in this run it reached 80.31% against 73.89% for the ingredient. It is not a cosmetic raw material, and the figure is evidence about the method, not a product comparison.

References

  1. Shaanxi Biocell General Testing Technology Co., Ltd. Test report G4814-2604274: collagen and CML endpoints in a glycated human skin explant model. 2026.

  2. Shin S, Lee J-A, Kim M, Kum H, Jung E, Park D. Anti-glycation activities of phenolic constituents from Silybum marianum (milk thistle) flower in vitro and on human explants. Molecules. 2015;20(3):3549–3564. doi:10.3390/molecules20033549

  3. Commission Regulation (EU) No 655/2013 of 10 July 2013 laying down common criteria for the justification of claims used in relation to cosmetic products. EUR-Lex

  4. Plamed Green Science Group. Technical data sheet: PMAnti-AGEs® Silibinin80 (PMKZ3101). 2026.

Ingredient Insights - Silibinin Anti-Glycation | Plamed's Insight